Table 2.
Incremental cases, deaths, and costs under a PCV13 versus PCV10 vaccination program over a 5-year time horizon
| Colombia* | Finland | The Netherlands | |
|---|---|---|---|
| Incremental | Incremental | Incremental | |
| Morbidity avoided | |||
| IPD | 5206 | 644 | 450 |
| Acute otitis media | 114,160 | 114,858 | 50,651 |
| Hospitalized pneumonia | 36,716 | 759 | 818 |
| Non-hospitalized pneumonia | – | 204 | 2072 |
| Total cases avoided | 156,082 | 116,465 | 53,991 |
| Mortality avoided | |||
| IPD | 1729 | 91 | 117 |
| Pneumonia | 1895 | 123 | 52 |
| Outcomes | |||
| Life years | 7011 | 413 | 260 |
| QALYs | 6406 | 1003 | 628 |
| Direct medical cost | |||
| Vaccination program cost | $20,439,100 | €13,429,808 | €25,466,659 |
| IPD | − $30,937,116 | − €5,711,294 | − €2,627,723 |
| AOM | − $2,930,124 | − €32,901,343 | − €885,025 |
| Pneumonia | − $46,407,970 | − €3,338,335 | − €4,208,818 |
| Net cost, direct medical | − $59,836,109 | − €28,521,153 | €17,745,594 |
| Incremental cost-effectiveness | |||
| Cost per life year | PCV13 dominant | PCV13 dominant | €68,142 |
| Cost per QALY | PCV13 dominant | PCV13 dominant | €28,260 |
*Costs for Colombia in US dollars